190 related articles for article (PubMed ID: 15979927)
21. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
22. Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: the Zoledronic Acid in Psoriatic Arthritis (ZAPA) Study.
McQueen F; Lloyd R; Doyle A; Robinson E; Lobo M; Exeter M; Taylor WJ; Jones P; Reid IR; Dalbeth N
Ann Rheum Dis; 2011 Jun; 70(6):1091-4. PubMed ID: 21342915
[TBL] [Abstract][Full Text] [Related]
23. Effect of zoledronic acid on bone pain secondary to metastatic bone disease.
Rotjanapan P
Med Health R I; 2009 Jan; 92(1):27-9. PubMed ID: 19248423
[No Abstract] [Full Text] [Related]
24. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Doggrell SA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
[TBL] [Abstract][Full Text] [Related]
25. Emerging strategies in bone health management for the adjuvant patient.
Coleman RE
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S11-6. PubMed ID: 18068485
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
[TBL] [Abstract][Full Text] [Related]
27. Pamidronate treatment of chronic noninfectious inflammatory lesions of the mandible in children.
Compeyrot-Lacassagne S; Rosenberg AM; Babyn P; Laxer RM
J Rheumatol; 2007 Jul; 34(7):1585-9. PubMed ID: 17611964
[TBL] [Abstract][Full Text] [Related]
28. Treatment with zoledronic acid ameliorates negative geometric changes in the proximal femur following acute spinal cord injury.
Shapiro J; Smith B; Beck T; Ballard P; Dapthary M; BrintzenhofeSzoc K; Caminis J
Calcif Tissue Int; 2007 May; 80(5):316-22. PubMed ID: 17417700
[TBL] [Abstract][Full Text] [Related]
29. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
Saad F; McKiernan J; Eastham J
Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
[TBL] [Abstract][Full Text] [Related]
30. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
Ottewell PD; Deux B; Mönkkönen H; Cross S; Coleman RE; Clezardin P; Holen I
Clin Cancer Res; 2008 Jul; 14(14):4658-66. PubMed ID: 18628481
[TBL] [Abstract][Full Text] [Related]
31. Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals.
Magopoulos C; Karakinaris G; Telioudis Z; Vahtsevanos K; Dimitrakopoulos I; Antoniadis K; Delaroudis S
Am J Otolaryngol; 2007; 28(3):158-63. PubMed ID: 17499130
[TBL] [Abstract][Full Text] [Related]
32. Bone turnover 18 months after a single intravenous dose of zoledronic acid.
Borba VZ; Paz-Filho G; Kulak CA; Seibel MJ; Bilezikian JP
Int J Clin Pract; 2007 Jun; 61(6):1058-62. PubMed ID: 17504370
[TBL] [Abstract][Full Text] [Related]
33. Gorham's disease of mandible--a rare case presentation in pediatric patient.
Mukhopadhyay S; Chattopadhyay A; Bhattacharya R; Roy U
J Indian Soc Pedod Prev Dent; 2016; 34(2):180-4. PubMed ID: 27080971
[TBL] [Abstract][Full Text] [Related]
34. The role of nurses in preserving patients' functional independence: Zoledronic acid--evidence and experience in metastatic bone disease.
Fitch MI
Eur J Oncol Nurs; 2007; 11 Suppl 2():S27. PubMed ID: 17804295
[No Abstract] [Full Text] [Related]
35. A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy.
Miwa S; Mizokami A; Konaka H; Izumi K; Nohara T; Namiki M
Jpn J Clin Oncol; 2009 Nov; 39(11):745-50. PubMed ID: 19808839
[TBL] [Abstract][Full Text] [Related]
36. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
Ryan CW; Huo D; Bylow K; Demers LM; Stadler WM; Henderson TO; Vogelzang NJ
BJU Int; 2007 Jul; 100(1):70-5. PubMed ID: 17552955
[TBL] [Abstract][Full Text] [Related]
37. Addition of bisphosphonate to antibiotic and anti-inflammatory treatment reduces bone resorption in experimental Staphylococcus aureus-induced arthritis.
Verdrengh M; Carlsten H; Ohlsson C; Tarkowski A
J Orthop Res; 2007 Mar; 25(3):304-10. PubMed ID: 17089391
[TBL] [Abstract][Full Text] [Related]
38. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia.
Perifanis V; Vyzantiadis T; Tziomalos K; Vakalopoulou S; Garipidou V; Athanassiou-Metaxa M; Harsoulis F
Ann Hematol; 2007 Jan; 86(1):23-30. PubMed ID: 17013645
[TBL] [Abstract][Full Text] [Related]
39. Biennial [corrected] IV zoledronic acid (Reclast) for prevention of osteoporosis.
Med Lett Drugs Ther; 2009 Jun; 51(1315):49. PubMed ID: 19556940
[No Abstract] [Full Text] [Related]
40. [New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].
Fukunaga M
Clin Calcium; 2009 Jan; 19(1):63-73. PubMed ID: 19122266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
